Very short versus longer dual antiplatelet treatment after coronary interventions: a systematic review and meta-analysis
G Tsigkas, A Apostolos, A Trigka… - American Journal of …, 2023 - Springer
Background Very short (≤ 3 months) duration of dual antiplatelet therapy (VSDAPT) has
recently been proposed after percutaneous coronary intervention (PCI) with drug-eluting …
recently been proposed after percutaneous coronary intervention (PCI) with drug-eluting …
6-versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: final results of the ITALIC trial (is there a life for …
R Didier, MC Morice, P Barragan, AAL Noryani… - Cardiovascular …, 2017 - jacc.org
Objectives The aim of this study was to test the hypothesis that 6-month dual antiplatelet
therapy (DAPT) is noninferior to 24-month DAPT in aspirin-sensitive patients. Background …
therapy (DAPT) is noninferior to 24-month DAPT in aspirin-sensitive patients. Background …
Details on the effect of very short dual antiplatelet therapy after drug-eluting stent implantation in patients with high bleeding risk: insight from the STOPDAPT-2 trial
H Watanabe, T Domei, T Morimoto, M Natsuaki… - Cardiovascular …, 2021 - Springer
Previously we briefly reported the effect of 1-month dual antiplatelet therapy (DAPT) for
patients with high bleeding risk (HBR) receiving percutaneous coronary intervention (PCI) in …
patients with high bleeding risk (HBR) receiving percutaneous coronary intervention (PCI) in …
Duration of dual antiplatelet therapy for patients at high bleeding risk undergoing PCI
Background The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous
coronary intervention (PCI) among patients at high bleeding risk (HBR) is unknown …
coronary intervention (PCI) among patients at high bleeding risk (HBR) is unknown …
Dual antiplatelet therapy duration based on ischemic and bleeding risks after coronary stenting
Background: Complex percutaneous coronary intervention (PCI) is associated with higher
ischemic risk, which can be mitigated by long-term dual antiplatelet therapy (DAPT) …
ischemic risk, which can be mitigated by long-term dual antiplatelet therapy (DAPT) …
Duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent: systematic review and network meta-analysis
Objective To evaluate the efficacy and safety of standard term (12 months) or long term (> 12
months) dual antiplatelet therapy (DAPT) versus short term (< 6 months) DAPT after …
months) dual antiplatelet therapy (DAPT) versus short term (< 6 months) DAPT after …
Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysis
M Valgimigli, PC Smits, E Frigoli… - European heart …, 2022 - academic.oup.com
Aim To assess the effects of 1-or≥ 3-month dual antiplatelet therapy (DAPT) in high
bleeding risk (HBR) patients who received biodegradable-polymer sirolimus-eluting stents …
bleeding risk (HBR) patients who received biodegradable-polymer sirolimus-eluting stents …
Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second …
D Giacoppo, Y Matsuda, LN Fovino… - European heart …, 2021 - academic.oup.com
Aims After percutaneous coronary intervention (PCI) with second-generation drug-eluting
stent (DES), whether short dual antiplatelet therapy (DAPT) followed by single antiplatelet …
stent (DES), whether short dual antiplatelet therapy (DAPT) followed by single antiplatelet …
Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE …
Summary Background A potent P2Y12 inhibitor-based dual antiplatelet therapy is
recommended for up to 1 year in patients with acute coronary syndrome receiving …
recommended for up to 1 year in patients with acute coronary syndrome receiving …
6-versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial
M Gilard, P Barragan, AAL Noryani, HA Noor… - Journal of the American …, 2015 - jacc.org
Background: The currently recommended duration of dual antiplatelet therapy (DAPT) in
drug-eluting stent (DES) recipients is 12 months to reduce the risk of late stent thrombosis …
drug-eluting stent (DES) recipients is 12 months to reduce the risk of late stent thrombosis …